Firefly Neuroscience (NASDAQ:AIFF) Trading Down 1.8% – Here’s Why

Firefly Neuroscience, Inc. (NASDAQ:AIFF) shares traded down 1.8% during mid-day trading on Friday . The stock traded as low as $1.09 and last traded at $1.10. 83,270 shares traded hands during trading, a decline of 60% from the average session volume of 206,779 shares. The stock had previously closed at $1.12.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Firefly Neuroscience in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Firefly Neuroscience currently has a consensus rating of “Sell”.

Firefly Neuroscience Stock Performance

The company has a 50 day simple moving average of $1.44 and a two-hundred day simple moving average of $2.30. The firm has a market cap of $14.84 million, a PE ratio of -0.53 and a beta of 1.85.

Firefly Neuroscience (NASDAQ:AIFF) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. The firm had revenue of $0.39 million during the quarter. Firefly Neuroscience had a negative return on equity of 319.00% and a negative net margin of 2,705.88%.

Insider Buying and Selling

In other news, major shareholder Windsor Private Capital Lp sold 78,031 shares of the company’s stock in a transaction on Wednesday, October 22nd. The shares were sold at an average price of $2.07, for a total value of $161,524.17. Following the sale, the insider directly owned 1,236,773 shares of the company’s stock, valued at $2,560,120.11. This represents a 5.93% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders have sold 295,064 shares of company stock worth $725,218. Insiders own 6.44% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in Firefly Neuroscience by 393.3% in the third quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock valued at $1,464,000 after purchasing an additional 401,085 shares during the last quarter. Savvy Advisors Inc. acquired a new position in shares of Firefly Neuroscience in the 3rd quarter valued at about $63,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Firefly Neuroscience by 92.9% in the 2nd quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock valued at $341,000 after buying an additional 58,067 shares during the period. 4.96% of the stock is currently owned by institutional investors and hedge funds.

About Firefly Neuroscience

Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.